In patients with EGFR-mutated NSCLC, tyrosine kinase inhibitors such as erlotinib and gefitinib are demonstrably effective first-line therapeutics.75,76 However, resistance mutations invariably develop. Here, EGFR is linked to non-small cell lung carcinoma.